DUBLIN–(BUSINESS WIRE)–The “Dysmenorrhea – Market Insight, Epidemiology and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This ‘Dysmenorrhea-Market Insights, Epidemiology and Market Forecast – 2030’ report delivers an in-depth understanding of the Dysmenorrhea, historical and forecasted epidemiology as well as the Dysmenorrhea market trends in the United States, EU-5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
The dysmenorrhea market report provides current treatment practices, emerging drugs, Dysmenorrhea market share of the individual therapies, current and forecasted Dysmenorrhea market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Dysmenorrhea treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.
The Dysmenorrhea epidemiology division provides the insights about historical and current Dysmenorrhea patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Dysmenorrhea epidemiology [segmented as Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea), Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea, Severity-specific Prevalent Cases of Primary dysmenorrhea, Severity-specific Prevalent Cases of Secondary dysmenorrhea, Treated cases of Primary and Secondary Dysmenorrhea] scenario of Dysmenorrhea in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Dysmenorrhea Emerging Drugs
Relugolix: Myovant Sciences GmbH/ Takeda
Myovant Sciences is developing its potential drug Relugolix, which is a small molecule consumed orally and its mechanism of action includes acting as a GnRH receptor antagonist, for the treatment of uterine fibroids and endometriosis. Relugolix is the most anticipated phase III program for the treatment of endometriosis-associated pain. For this candidate, Takeda has commercial rights for Japan along with some parts of Asia. In other regions, Myovant Sciences holds commercialization rights. Myovant was formed by Takeda and Roivant Sciences in June 2016.
Yselty (Linzagolix; OBE2109): ObsEva
Yselty (previously known as Linzagolixx, OBE2109) by ObsEva is a novel, oral, once-daily, GnRH receptor antagonist with the tagline best-in-class profile. As per the company, the aspect which makes it different from the other marketed GnRH, is that it has the potential to provide effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments.
FSN-013 (Estetrol/ Drospirenone): Fuji Pharma
FSN-013 is a 5th generation combined oral contraceptive drug of Fuji Pharma composed of estetrol (a natural estrogen) and drospirenone. As of now, it has exhibited some of the eye-catching characteristics such as improved bleeding control as compared to other drugs. Along with this, it also has lower lipid impact, and lower interaction among other drugs.
Pure Femme Tablets: Pure Green
Pure Green Pharmaceuticals is an emerging the US-based biotech start-up, at the forefront of research into the therapeutic qualities of cannabis. Currently, a phase II (NCT04091789) clinical trial is in its recruiting stage which is anticipated to include 30 patients.
Dysmenorrhea Market Outlook
Dysmenorrhea market in the 7MM is expected to change in the study period 2017-2030.The therapeutic market of Dysmenorrhea in seven major markets was found to be USD 7,430 million in 2017 which is expected to increase during study period (2017-2030).
Key Topics Covered:
1. Key Insights
2. Executive Summary of Dysmenorrhea
3. SWOT Analysis
4. Epidemiology and Market Methodology
5. Dysmenorrhea: Market Share (%) Distribution Overview at a Glance: By Country
6. Dysmenorrhea: Disease Background and Overview
6.1. Types of Dysmenorrhea
6.2. Risk Factors
6.3. Signs and Symptoms
6.6. Diagnostic Algorithm
6.7. Diagnostic Guidelines
6.7.1. National Institute for Health and Care Excellence (NICE) Guidelines
7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale
7.3. Epidemiology Scenario: 7MM
8. Current Treatment Practices
8.1. Pharmacological Treatments
8.1.2. Hormonal contraception
8.1.3. Gonadotropin-releasing hormone (GnRH) analogs
8.2.1. Removal of the uterus (hysterectomy) and ovaries (oophorectomy)
8.2.2. Laparoscopic uterine nerve ablation and laparoscopic presacral neurectomy
8.3. Non-Pharmacological Treatments
8.3.1. Transcutaneous electrical nerve stimulation (TENS)
8.3.2. Supportive Therapies
8.4. Treatment Algorithms
8.5. Guideline of Dysmenorrhea
8.5.1. American College of Obstetricians and Gynecologists (ACOG) recommendations for Dysmenorrhea and Endometriosis in the Adolescent
8.5.2. NICE Recommendations: Endometriosis (2017)
8.5.3. Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2017 edition
8.5.4. Guideline of the European Society of Human Reproduction and Embryology (ESHRE) for Endometriosis-associated pain: 2013
9. Unmet Needs
10. Patient Journey
11. Key Endpoints in Dysmenorrhea Clinical Trials
12. Marketed Therapies
12.1. Marketed Key Cross
12.2. Orilissa (Elagolix): AbbVie/ Neurosciences Biosciences
12.2.1. Product Description
12.2.2. Regulatory Milestones
12.2.3. Other Developmental Activities
12.2.4. Pivotal Clinical Trial
12.2.5. Ongoing Clinical Trial Activity
12.3. Jemina Tablets (levonorgestrel – ethinylestradiol compound formulation): Nobelpharma/ASKA Pharmaceutical
12.4. Visanne (Dinagest): Mochida/Bayer Schering Pharma AG
13. Emerging Therapies
13.1. Yselty (Linzagolix; OBE2109): ObsEva
13.1.1. Product Description
13.1.2. Other Developmental Activities
13.1.3. Clinical Development
13.1.4. Safety and Efficacy
13.2. Relugolix (TAK-385): Myovant Sciences/Takeda
13.3. Pure Femme Tablets: Pure Green
13.4. FSN-013 (Estetrol/ Drospirenone): Fuji Pharma
13.5. NS-580: Nippon Shinyaku
14. Conjoint Analysis of Dysmenorrhea Therapies
15. Dysmenorrhea: Seven Major Market Analysis
15.1. Key Findings
15.2. Market Outlook
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/pql54m
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900